Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515903-21-00

Acronym

20240124

Enrollment

Registered

2025-09-30

Start date

2025-10-31

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Greece, Hungary, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026